Axsome Therapeutics Inc
AXSM134.210USD
-0.720-0.53%
Market hours （ET）Quotes delayed by 15 min
6.75BMarket Cap
LossP/E TTM
More Details of Axsome Therapeutics Inc Company
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Axsome Therapeutics Inc Info
Ticker SymbolAXSM
Company nameAxsome Therapeutics Inc
IPO dateNov 19, 2015
CEODr. Herriot Tabuteau, M.D.
Number of employees683
Security typeOrdinary Share
Fiscal year-endNov 19
AddressOne World Trade Center, 29Th Floor
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10007
Phone12123323241
Websitehttps://www.axsome.com/
Ticker SymbolAXSM
IPO dateNov 19, 2015
CEODr. Herriot Tabuteau, M.D.
Company Executives of Axsome Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-18.97%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-100.00%
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-18.97%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-100.00%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
By BusinessUSD
Name
Revenue
Proportion
Auvelitv
119.64M
80.32%
Sunosi
28.91M
19.41%
Sunosi royality revenue
1.08M
0.73%
Sunosi License revenue
410.00K
0.28%
By RegionUSD
Name
Revenue
Proportion
United States
146.45M
98.31%
Outside of the United States
2.51M
1.69%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Auvelitv
119.64M
80.32%
Sunosi
28.91M
19.41%
Sunosi royality revenue
1.08M
0.73%
Sunosi License revenue
410.00K
0.28%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Antecip Capital, L.L.C.
14.72%
The Vanguard Group, Inc.
7.89%
BlackRock Institutional Trust Company, N.A.
6.30%
BVF Partners L.P.
3.39%
RTW Investments L.P.
3.04%
Other
64.67%
Shareholders
Shareholders
Proportion
Antecip Capital, L.L.C.
14.72%
The Vanguard Group, Inc.
7.89%
BlackRock Institutional Trust Company, N.A.
6.30%
BVF Partners L.P.
3.39%
RTW Investments L.P.
3.04%
Other
64.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.57%
Investment Advisor/Hedge Fund
20.19%
Hedge Fund
14.82%
Corporation
14.72%
Research Firm
2.77%
Private Equity
1.26%
Individual Investor
1.14%
Pension Fund
1.13%
Sovereign Wealth Fund
0.94%
Other
7.46%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
633
38.77M
77.68%
-3.42M
2025Q2
615
46.46M
93.12%
-4.77M
2025Q1
613
46.35M
94.71%
-3.83M
2024Q4
570
46.09M
94.52%
-5.46M
2024Q3
540
47.31M
97.60%
-6.48M
2024Q2
526
49.58M
103.45%
-2.44M
2024Q1
512
47.53M
101.57%
-4.95M
2023Q4
484
47.45M
101.62%
-3.96M
2023Q3
475
47.05M
100.91%
-2.63M
2023Q2
475
45.53M
98.82%
+628.64K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Antecip Capital, L.L.C.
7.34M
14.72%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
3.94M
7.89%
+67.64K
+1.75%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.14M
6.3%
+173.97K
+5.86%
Jun 30, 2025
BVF Partners L.P.
1.69M
3.39%
--
--
Jun 30, 2025
RTW Investments L.P.
1.52M
3.04%
-1.41M
-48.10%
Jun 30, 2025
Macquarie Investment Management
1.14M
2.28%
+161.49K
+16.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
989.45K
1.98%
+54.60K
+5.84%
Jun 30, 2025
State Street Investment Management (US)
958.50K
1.92%
+52.48K
+5.79%
Jun 30, 2025
Fairmount Funds Management LLC
815.18K
1.63%
--
--
Jun 30, 2025
Deep Track Capital LP
801.37K
1.61%
+801.37K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.03%
ALPS Medical Breakthroughs ETF
3.66%
SPDR S&P Pharmaceuticals ETF
2.35%
Virtus LifeSci Biotech Products ETF
1.9%
iShares U.S. Pharmaceuticals ETF
1.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.76%
iShares Health Innovation Active ETF
0.65%
ProShares Ultra Nasdaq Biotechnology
0.63%
Invesco Nasdaq Biotechnology ETF
0.61%
First Trust Mid Cap Growth AlphaDEX Fund
0.48%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.03%
ALPS Medical Breakthroughs ETF
Proportion3.66%
SPDR S&P Pharmaceuticals ETF
Proportion2.35%
Virtus LifeSci Biotech Products ETF
Proportion1.9%
iShares U.S. Pharmaceuticals ETF
Proportion1.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.76%
iShares Health Innovation Active ETF
Proportion0.65%
ProShares Ultra Nasdaq Biotechnology
Proportion0.63%
Invesco Nasdaq Biotechnology ETF
Proportion0.61%
First Trust Mid Cap Growth AlphaDEX Fund
Proportion0.48%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
